

Steffen LÄjck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5754115/publications.pdf>

Version: 2024-02-01

125
papers

4,835
citations

172386

29
h-index

110317

64
g-index

131
all docs

131
docs citations

131
times ranked

6420
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€”staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	2.6	26
2	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.3	5
3	Personalised radiation therapy taking both the tumour and patient into consideration. <i>Radiotherapy and Oncology</i> , 2022, 166, A1-A5.	0.3	7
4	Plasticity within Aldehyde Dehydrogenaseâ€”Positive Cells Determines Prostate Cancer Radiosensitivity. <i>Molecular Cancer Research</i> , 2022, 20, 794-809.	1.5	8
5	Cellular plasticity upon proton irradiation determines tumor cell radiosensitivity. <i>Cell Reports</i> , 2022, 38, 110422.	2.9	10
6	Response to comment on â€œBiomarker signatures for primary radiochemotherapy of locally advanced HNSCCâ€•. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
7	Experimental validation of 4D log fileâ€”based proton dose reconstruction for interplay assessment considering amplitudeâ€”sorted 4DCTs. <i>Medical Physics</i> , 2022, 49, 3538-3549.	1.6	8
8	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€” Hypothesis generation on a multicentre cohort of the DKTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.3	5
9	Radiomics-based tumor phenotype determination based on medical imaging and tumor microenvironment in a preclinical setting. <i>Radiotherapy and Oncology</i> , 2022, 169, 96-104.	0.3	11
10	Subjective memory impairment in glioma patients with curative radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
11	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
12	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
13	Beam pulse structure and dose rate as determinants for the flash effect observed in zebrafish embryo. <i>Radiotherapy and Oncology</i> , 2022, 173, 49-54.	0.3	26
14	Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia. <i>Acta OncolÃ³gica</i> , 2022, 61, 856-863.	0.8	4
15	Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models. <i>Scientific Reports</i> , 2022, 12, .	1.6	16
16	A Novel 2-Metogene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	1.7	2
17	Results of aâ€”randomized controlled phaseâ€”III trial: efficacy of polyphenol-containing cystusÃ® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 63-73.	1.0	10
18	Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial. <i>Radiotherapy and Oncology</i> , 2021, 155, 285-292.	0.3	12

#	ARTICLE	IF	CITATIONS
19	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
20	Dual role of ER stress in response to metabolic co-targeting and radiosensitivity in head and neck cancer cells. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3021-3044.	2.4	8
21	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 204-211.	0.3	5
22	The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. <i>Medical Sciences Forum</i> , 2021, 3, .	0.5	0
23	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
24	Do We Need Complex Image Features to Personalize Treatment of Patients with Locally Advanced Rectal Cancer?. <i>Lecture Notes in Computer Science</i> , 2021, , 775-785.	1.0	2
25	Radiation oncology in the new virtual and digital era. <i>Radiotherapy and Oncology</i> , 2021, 154, A1-A4.	0.3	8
26	Modelling of late side-effects following cranial proton beam therapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 15-23.	0.3	6
27	Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. <i>Radiotherapy and Oncology</i> , 2021, 158, 262-267.	0.3	4
28	Value of functional in-vivo endpoints in preclinical radiation research. <i>Radiotherapy and Oncology</i> , 2021, 158, 155-161.	0.3	3
29	Electron dose rate and oxygen depletion protect zebrafish embryos from radiation damage. <i>Radiotherapy and Oncology</i> , 2021, 158, 7-12.	0.3	26
30	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. <i>Oncogene</i> , 2021, 40, 4214-4228.	2.6	27
31	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.3	2
32	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. <i>Radiotherapy and Oncology</i> , 2021, 160, 69-77.	0.3	8
33	An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication. <i>Nature Cancer</i> , 2021, 2, 709-722.	5.7	41
34	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	1.0	16
35	In reply to the Letter to the Editor by Chen and Lui regarding "Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial" by A Dietrich et al.. <i>Radiotherapy and Oncology</i> , 2021, 161, 261-262.	0.3	0
36	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1351-1360.	3.2	15

#	ARTICLE	IF	CITATIONS
37	Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. <i>EJNMMI Research</i> , 2021, 11, 109.	1.1	32
38	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5595.	1.7	4
39	Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO <i>in silico</i> study. <i>British Journal of Radiology</i> , 2020, 93, 20190879.	1.0	13
40	Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 143, 44-50.	0.3	5
41	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
42	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 52-59.	1.2	2
43	Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines. <i>Theranostics</i> , 2020, 10, 7599-7621.	4.6	11
44	Pictures worth more than a thousand words: Prediction of survival in medulloblastoma patients. <i>EBioMedicine</i> , 2020, 62, 103136.	2.7	2
45	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 262-267.	0.3	12
46	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19
47	The prevalence of extramedullary acute myeloid leukemia detected by ¹⁸ F-FDG-PET/CT: final results from the prospective PETAML trial. <i>Haematologica</i> , 2020, 105, 1552-1558.	1.7	31
48	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 189-196.	0.3	41
49	Applying Tissue Slice Culture in Cancer Research—Insights from Preclinical Proton Radiotherapy. <i>Cancers</i> , 2020, 12, 1589.	1.7	15
50	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. <i>Radiology</i> , 2020, 295, 328-338.	3.6	1,869
51	Specific requirements for translation of biological research into clinical radiation oncology. <i>Molecular Oncology</i> , 2020, 14, 1569-1576.	2.1	6
52	Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. <i>Radiotherapy and Oncology</i> , 2020, 143, 108-116.	0.3	24
53	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	1.2	10
54	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. <i>Cancers</i> , 2020, 12, 871.	1.7	9

#	ARTICLE	IF	CITATIONS
55	An Integrative Analysis of Image Segmentation and Survival of Brain Tumour Patients. Lecture Notes in Computer Science, 2020, , 368-378.	1.0	5
56	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Research, 2020, 10, 135.	1.1	11
57	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. Radiotherapy and Oncology, 2019, 130, 164-171.	0.3	27
58	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. Radiotherapy and Oncology, 2019, 130, 10-17.	0.3	44
59	^{68}Ga -RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.3	9
60	Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual γH2AX . Radiotherapy and Oncology, 2019, 139, 94-100.	0.3	11
61	Analysing Tumour Growth Delay Data from Animal Irradiation Experiments with Deviations from the Prescribed Dose. Cancers, 2019, 11, 1281.	1.7	4
62	Assessing robustness of radiomic features by image perturbation. Scientific Reports, 2019, 9, 614.	1.6	166
63	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	3.2	53
64	Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer. Radiotherapy and Oncology, 2019, 131, 120-126.	0.3	3
65	Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy. Clinical and Translational Radiation Oncology, 2019, 18, 113-119.	0.9	1
66	Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. Radiotherapy and Oncology, 2019, 137, 24-31.	0.3	10
67	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. Clinical and Translational Radiation Oncology, 2019, 16, 40-47.	0.9	32
68	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. Acta Oncologica, 2019, 58, 916-925.	0.8	11
69	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. Radiotherapy and Oncology, 2019, 135, 43-50.	0.3	25
70	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. Clinical and Translational Radiation Oncology, 2019, 15, 108-112.	0.9	9
71	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. European Journal of Cancer, 2019, 110, 11-20.	1.3	44
72	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. British Journal of Radiology, 2019, 92, 20180539.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019, 75, 548-551.	0.9	36
74	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , 2019, 130, 97-103.	0.3	14
75	Competing risks in survival data analysis. <i>Radiotherapy and Oncology</i> , 2019, 130, 185-189.	0.3	31
76	Comparison of subjective evaluation versus objective algorithm in the interpretation of follow-up FDG-PET/CT scans after radiochemotherapy in head and neck cancer patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 93-100.	0.3	3
77	Why validation of prognostic models matters?. <i>Radiotherapy and Oncology</i> , 2018, 127, 370-373.	0.3	43
78	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17
79	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	3.2	45
80	Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 393-406.	1.9	25
81	Retrospective investigation of the prognostic value of the α 2 β 1 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy. <i>PLoS ONE</i> , 2018, 13, e0209479.	1.1	5
82	Heterogeneity of γ H2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2616.	1.8	5
83	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 437-444.	0.3	10
84	Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1813-1822.	3.3	12
85	The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 7-12.	0.9	8
86	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
87	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , 2017, 124, 533-540.	0.3	123
88	Potential proton and photon dose degradation in advanced head and neck cancer patients by intratherapy changes. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 104-113.	0.8	31
89	Tumor heterogeneity determined with a γ H2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. <i>Radiotherapy and Oncology</i> , 2017, 124, 379-385.	0.3	11
90	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. <i>Radiotherapy and Oncology</i> , 2017, 124, 496-503.	0.3	21

#	ARTICLE	IF	CITATIONS
91	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 36-42.	0.9	9
92	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 285-299.	0.6	5
93	Physical correction model for automatic correction of intensity non-uniformity in magnetic resonance imaging. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 4, 32-38.	1.2	7
94	Session 39: Modelling and simulation III. <i>Biomedizinische Technik</i> , 2017, 62, .	0.9	0
95	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. <i>Radiation Oncology</i> , 2017, 12, 190.	1.2	25
96	Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability. <i>Oncotarget</i> , 2016, 7, 73292-73308.	0.8	9
97	Precise image-guided irradiation of small animals: a flexible non-profit platform. <i>Physics in Medicine and Biology</i> , 2016, 61, 3084-3108.	1.6	39
98	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.3	130
99	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 19-26.	0.9	22
100	Evaluation of a deformable registration algorithm for subsequent lung computed tomography imaging during radiochemotherapy. <i>Medical Physics</i> , 2016, 43, 5028-5039.	1.6	9
101	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , 2016, 121, 447-452.	0.3	8
102	PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 543.	0.7	20
103	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	3.2	127
104	Experimental Observation of Resonance-Assisted Tunneling. <i>Physical Review Letters</i> , 2015, 115, 104101.	2.9	26
105	Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. <i>Radiation Oncology</i> , 2015, 10, 172.	1.2	36
106	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 256.	1.3	18
107	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1165-1174.	0.4	89
108	Corrigendum to “HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)” [Radiother. Oncol. 113 (2014) 317–323]. <i>Radiotherapy and Oncology</i> , 2015, 114, 419.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Implementation of a software for REmote COMparison of PARTicle and photon treatment plans: ReCompare. Zeitschrift Fur Medizinische Physik, 2015, 25, 287-294.	0.6	9
110	Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. Journal of Nuclear Medicine, 2015, 56, 1150-1156.	2.8	59
111	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. Acta OncolÃ³gica, 2015, 54, 1658-1664.	0.8	36
112	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
113	Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer. Strahlentherapie Und Onkologie, 2014, 190, 263-269.	1.0	15
114	Concept for individualized patient allocation: ReCompareâ€™remote comparison of particle and photon treatment plans. Radiation Oncology, 2014, 9, 59.	1.2	16
115	Integrable approximation of regular islands: The iterative canonical transformation method. Physical Review E, 2013, 88, 062901.	0.8	6
116	Complex paths for regular-to-chaotic tunnelling rates. Europhysics Letters, 2013, 102, 10005.	0.7	15
117	Coupling of bouncing-ball modes to the chaotic sea and their counting function. Physical Review E, 2012, 85, 016210.	0.8	5
118	Consequences of flooding on spectral statistics. Physical Review E, 2012, 85, 036213.	0.8	5
119	Partial Weyl law for billiards. Europhysics Letters, 2011, 94, 30004.	0.7	7
120	Fractional-Power-Law Level Statistics Due to Dynamical Tunneling. Physical Review Letters, 2011, 106, 024101.	2.9	9
121	Regular-to-Chaotic Tunneling Rates: From the Quantum to the Semiclassical Regime. Physical Review Letters, 2010, 104, 114101.	2.9	79
122	Direct regular-to-chaotic tunneling rates using the fictitious-integrable-system approach. Physical Review E, 2010, 82, 056208.	0.8	33
123	Quality factors and dynamical tunneling in annular microcavities. Physical Review A, 2009, 79, .	1.0	44
124	Dynamical Tunneling in Mushroom Billiards. Physical Review Letters, 2008, 100, 174103.	2.9	81
125	Regular-to-Chaotic Tunneling Rates Using a Fictitious Integrable System. Physical Review Letters, 2008, 100, 104101.	2.9	63